Interestingly, recent studies suggest that the therapeutic efficacy of anti-tumor necrosis factor-α therapies may result from the inhibition of CCL20 in rheumatoid arthritis synovium [33] as this chemokine mediates key pathogenic events such as the recruitment of Th17 cells to the inflamed joints [32]. This evidence concerns the gene CCL20 and rheumatoid arthritis.